Medivir AB (publ) is a Sweden-based biotechnology company focused on the discovery, development and commercialization of innovative pharmaceuticals in the fields of oncology and viral diseases. The company’s expertise lies in small-molecule chemistry and targeted drug design, with particular emphasis on liver-directed therapies and protease inhibitors. Medivir operates a research facility in Huddinge, Sweden, where it advances its proprietary platform technologies to identify new candidate molecules.
Historically, Medivir gained prominence through the discovery of simeprevir, a hepatitis C virus protease inhibitor that was licensed to Janssen Pharmaceuticals and marketed under the brand name Olysio. Building on this success, the company has transitioned its pipeline toward oncology by developing a liver-targeted polymerase inhibitor, MIV-818, which entered early clinical studies for primary and secondary liver cancers. Additional preclinical programs are exploring novel mechanisms of action against solid tumors.
Medivir collaborates with global pharmaceutical partners to leverage its medicinal chemistry know-how and accelerate clinical development. Its strategic alliances extend across Europe and North America, enabling access to global trial networks and regulatory expertise. The company is publicly listed on Nasdaq Stockholm and maintains a dedicated corporate governance framework in line with Swedish and European regulations.
Underpinning its operations is a commitment to rigorous research and translational science. Medivir’s multidisciplinary team of chemists, biologists and clinicians works to advance its oncology portfolio through proof-of-concept studies, with the goal of delivering differentiated therapies for patients with unmet medical needs. The company continues to explore new targets and expand its pipeline via in-house discovery and external collaborations.
AI Generated. May Contain Errors.
